Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,886.41
(
0.00%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 171214

Thursday, 12/12/2013 2:08:46 PM

Thursday, December 12, 2013 2:08:46 PM

Post# of 257268

There is a chance GILD could have comparable efficacy [to ABBV/ENTA’s regimen] without ribavirin or with 8 weeks duration…

Thanks for chiming in. Just to be clear: Of GILD’s three phase-3 trials for the all-oral NDA in GT1, only the ION-3 trial is testing an 8-week treatment duration, and ION-3 is restricted to treatment-naïve patents without cirrhosis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today